| | | 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万 元（含），本次回购股份的价格不超过 18.75 元/股（含），本次回购的股份用于 员工持股计划或股权激励，回购股份实施期限为自公司股东大会审议通过本次回 购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 29 日披露的《健 友股份关于以集中竞价交易方式回购股份的预案》（公告编号：2025-028）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 6 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 88 万股，已回购股份占公司总股本的比例为 0.05%，成交最 低价为 11.58 元/股，成交最高价为 11.66 元/股，支付的总金额为人民币 1,022.07 万元（不含交易费用及 ...

Core Viewpoint - The announcement details the conversion results of the "Jianyou Convertible Bonds" and the changes in the company's share capital as of June 30, 2025, highlighting the low conversion rate and the significant amount of unconverted bonds [1][2][3]. Summary by Sections Conversion Situation - As of June 30, 2025, a total of RMB 719,000 worth of "Jianyou Convertible Bonds" has been converted into common shares, resulting in 18,035 shares, which represents 0.001% of the total shares before conversion [2][6]. - The total amount of "Jianyou Convertible Bonds" that has not been converted is RMB 502,464,000, accounting for 99.86% of the total issuance [3][6]. Convertible Bond Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 503.19 million, with a maturity of 6 years, approved by the China Securities Regulatory Commission [4]. - The bonds were listed on the Shanghai Stock Exchange on May 22, 2020, under the code "113579" [4]. Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price to RMB 24.34 per share as of June 5, 2025 [5].

Summary of Key Points Core Viewpoint - The announcement details the conversion results and share changes related to the "Jianyou Convertible Bonds" issued by Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd, highlighting the low conversion rate and the remaining unconverted bonds. Group 1: Conversion Status - As of June 30, 2025, a total of RMB 719,000 of "Jianyou Convertible Bonds" have been converted into ordinary shares, with RMB 7,000 of the bonds being repurchased [1][3] - The amount of unconverted "Jianyou Convertible Bonds" as of June 30, 2025, is RMB 502,464,000, which represents 99.86% of the total issuance [1][3] Group 2: Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 5.0319 billion, with a maturity of 6 years, approved by the China Securities Regulatory Commission [1][2] - The bonds were listed on the Shanghai Stock Exchange starting from May 22, 2020, under the code "113579" [1][2] Group 3: Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price down to RMB 24.34 per share effective from June 5, 2025 [2][3] Group 4: Share Capital Changes - The total share capital remained unchanged at 1,615,634,969 shares as of June 30, 2025, with no new shares issued from the conversion of the bonds [4]

重要内容提示： 转股情况： 截至 2025 年 6 月 30 日，累计已有人民币 719,000 元"健友转债"转为公司 普通股，累计回售人民币 7,000 元"健友转债"。"健友转债"累计转股股数 18,035 股，占转股前公司股份总额的 0.001%。 未转股可转债情况： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 截至 2025 年 6 月 30 日，尚未转股的"健友转债"金额为人民币 502,464,000 元，占"健友转债"发行总量的比例为 99.86%。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简 ...

Group 1 - The core viewpoint of the announcement is that the credit rating for Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.'s convertible bonds remains unchanged at "AA" with a stable outlook [2][3]. - The previous rating for "Jianyou Convertible Bonds" was also "AA" with a stable outlook, indicating consistency in the company's creditworthiness [3]. - The tracking credit rating was conducted by United Credit Rating Co., Ltd., which assessed the company's business, management, and financial situation before issuing the report on June 27, 2025 [3]. Group 2 - The announcement confirms that the company's credit rating and the rating for the convertible bonds have not changed since the last assessment on June 26, 2024 [2][3]. - The report is available for further details on the Shanghai Stock Exchange website [3]. - The announcement was officially made by the board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. on June 28, 2025 [5].

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. maintains a stable credit rating of AA for both the company and its convertible bonds, reflecting its strong market position in heparin production and sales, despite facing challenges in raw material pricing and market fluctuations [1][3][4]. Company Overview - The company specializes in the research, production, and sales of a full range of heparin products, including heparin sodium raw materials and low molecular weight heparin preparations, along with anti-tumor preparations and other sterile injectables [7][12]. - As of the end of 2024, the company reported total assets of 95.10 billion yuan and total equity of 64.88 billion yuan, with an operating income of 39.24 billion yuan and a profit of 9.92 billion yuan [7][12]. Financial Performance - In 2024, the company achieved a total profit of 9.92 billion yuan, recovering from a loss in the previous year, with a gross profit margin of 43.28%, although this was a decline from 48.45% in 2023 [5][14]. - The company’s total debt decreased by 20.68% to 20.79 billion yuan by the end of 2024, with a cash-to-short-term debt ratio of 1.67, indicating strong liquidity [5][14]. Market Position and Industry Analysis - The global heparin market is projected to grow at a compound annual growth rate (CAGR) of 5% to 7%, driven by an aging population and increasing prevalence of cardiovascular diseases [11][12]. - The company holds a competitive advantage in research and development, with 49 ongoing projects and a research investment of 532 million yuan, accounting for 13.57% of total revenue in 2024 [4][5]. Risks and Challenges - The company faces risks related to raw material supply, currency fluctuations, and trade tensions, particularly with a significant portion of its revenue (76.75% in 2024) coming from overseas sales [4][6]. - The price of standard heparin raw materials has been on a downward trend, impacting the company's revenue from this segment, which decreased by 21.05% to 7.87 billion yuan in 2024 [14][19]. Future Outlook - The company is expected to enhance its competitive edge as it expands its formulation business and continues to launch new pharmaceutical products [3][11]. - The stable cash reserves and reduced debt burden suggest that the company’s ability to service its convertible bonds will remain strong, with potential for credit rating upgrades if overseas market expansion and capital strength improve significantly [3][4].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has announced the results of the credit rating for its convertible bonds, maintaining a rating of "AA" for both the bonds and the company itself, with a stable outlook [1][2] - The previous tracking rating for the "Jianyou Convertible Bonds" was conducted on June 26, 2024, with the same ratings of "AA" and a stable outlook [1] - The credit rating agency, United Credit Rating Co., Ltd., performed a comprehensive analysis of the company's business, management, and financial conditions before issuing the 2025 tracking rating report on June 27, 2025 [2]

重要内容提示： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于公司公开发行可转换公司债券 2025年跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ●本次评级结果未发生调整。 ●前次"健友转债"评级：AA；主体评级：A A；评级展望：稳定； 本次"健友转债"评级：AA；主体评级：A A；评级展望：稳定。 根据《上市公司证券发行管理办法》等有关规定，南京健友生化制药股份有 限公司（以下简称"公司"）委托信用评级机构联合资信评估股份有限公司对公 司 2020 年 4 月发行的可转换公司债券（以下简称"健友转债"）进行了跟踪信 用评级。 "健友转债"前次跟踪评级时间为 2024 年 6 月 26 日，前次公司主体信用评 级结果为"AA"、前次评级展望为"稳定"，前次"健友转债"债券信用等级 为"AA"，评级机构为联合资信评估股份有限公 ...

南京健友生化制药股份有限公司 公开发行可转换公司债券 2025 年跟踪评级报告 1 www.lhratings.com 联合〔2025〕5678 号 联合资信评估股份有限公司通过对南京健友生化制药股份有限 公司主体及其相关债券的信用状况进行跟踪分析和评估，确定维持 南京健友生化制药股份有限公司主体长期信用等级为 AA，维持"健 友转债"信用等级为 AA，评级展望为稳定。 特此公告 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十六日 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信 基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事 实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真 实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告 在资料信息获取、评级方法与模型、未来事项预测评估等方面存在局限性。 二、本报告系联合资信接受南京健友生化制药股份有限公司（以下简称 "该公司"）委托所出具，除因本次评级事项联合资信与该公司构成评级委 托关系外，联合资信、评级人员与该公司 ...

Core Viewpoint - The announcement details the results of the "Jianyou Convertible Bond" repurchase option, indicating that there were no valid repurchase applications during the specified period, resulting in no financial impact on the company [1][2][3] Group 1: Repurchase Announcement - The repurchase price for the "Jianyou Convertible Bond" was set at 100.30 RMB per bond, including accrued interest and tax [2] - The repurchase application period was from June 17, 2025, to June 23, 2025, and the application ended after the market closed on June 23, 2025 [2][3] Group 2: Repurchase Results - During the repurchase application period, the effective number of repurchase applications was 0 bonds, resulting in a total repurchase amount of 0 RMB [2][3] - The company will not need to process any payments to investors regarding the repurchase, as the repurchase has been completed [2][3] Group 3: Future Matters - The unrepurchased "Jianyou Convertible Bonds" will continue to be traded on the Shanghai Stock Exchange [2]